Clinics frequently ask what they need to buy in order to offer menopause care. It is the wrong first question, and the answer is usually very little.
What a menopause service actually consists of is a consistent assessment pathway, enough appointment time to use it, a defined scope, and a follow-up structure. This article sets out each of those.
In Brief:
| A menopause service is defined by its assessment pathway, not by the treatments it offers. |
| The first visit needs more time than a standard appointment, and the follow-up cadence matters more than the initial decision. |
| Most of what you need is documentation, protocols and staff clarity rather than equipment. |
| Decide your scope before you open the service, including what you will refer out. |
Define your scope before you launch
Deciding this early prevents most of the problems that arise later. A workable scope statement answers three questions: which patients you will manage, which you will co-manage, and which you will refer.
Most practices adding this service can competently manage symptomatic perimenopausal and postmenopausal patients without significant complicating factors. Referral or co-management is appropriate for patients with a history of hormone-sensitive cancer, unexplained abnormal bleeding, complex cardiovascular or thrombotic history, suspected primary ovarian insufficiency, and any patient whose presentation does not fit.
Write it down. A scope that lives only in the lead clinician’s head is not a scope.
The assessment pathway is the service
What distinguishes a menopause service from an ad hoc conversation is that every patient goes through the same structured assessment.
That assessment covers the menstrual and reproductive history, the full symptom picture across body systems rather than the presenting complaint alone, personal and family medical history relevant to treatment eligibility, current medications and supplements, screening status, and the patient’s own goals and preferences.
It also covers exclusions. Thyroid function and a complete blood count are reasonable baseline considerations, because thyroid disease and anemia overlap almost entirely with the menopause symptom list. Depression warrants assessment in its own right rather than absorption into a menopause diagnosis, and sleep apnea is under-diagnosed in women and more common after menopause.
One point worth stating explicitly to your team: in women over 45, perimenopause is identified from history and symptom pattern rather than from a hormone level. Follicle-stimulating hormone fluctuates too widely for a single reading to be conclusive. Routine hormone panels are not a diagnostic pathway, and selling them as one is a reputational risk.
Visit structure and time
The initial consultation does not fit into a standard slot. Practices that try to run it in 15 minutes generally end up with an incomplete history and a rushed treatment conversation, which is the worst of both.
A realistic structure allocates a longer first appointment for assessment and education, a shorter second appointment to review any investigations and agree on a plan, and a review at around three months to assess response.
The three-month review is the part most often omitted and the part that determines whether the service works. Treatment in this area is iterative. The first option is not always the right option, and the purpose of the review is to establish whether everything feels better and nothing feels worse.
What you actually need in place
The requirements are mostly administrative and educational rather than physical.
- A trained clinician, with foundational education covering the physiology, assessment, treatment options and long-term implications.
- Written protocols for assessment, treatment selection, follow-up cadence and escalation.
- Documentation and consent materials appropriate to the treatments you offer.
- Patient education materials, so that explanation does not depend on how much time the clinician has that day.
- A referral network, including a menopause-certified colleague, gynecology, and oncology where relevant.
- Front-desk clarity on what the service is, what an appointment involves, and how long it takes.
Practices offering prescription treatment also need to settle pharmacy arrangements and any laboratory pathways in advance. This is one of the areas where implementation support saves the most time, because the operational detail is where launches stall.
What to decide about pricing and access
Pricing models vary by practice type and by state, and we would not presume to prescribe one. What matters is that the model is decided before launch rather than negotiated per patient, and that the patient understands what the appointment costs and what it includes.
One structural consideration: because follow-up is integral rather than optional, a pricing model that makes review appointments feel like an additional purchase tends to undermine the clinical pathway.
How to know whether it is working
Symptom response is the primary measure, and it should be recorded rather than remembered. Practices that track a simple symptom score at baseline and at review can see whether their pathway is producing results.
Beyond that, the useful indicators are the proportion of patients who attend their three-month review, the proportion whose initial treatment is adjusted, and where referrals are going. If nothing is ever adjusted, the review is probably not doing its job.
Long enough for a full history, a symptom review across body systems, and an education conversation. Practices commonly find a standard slot insufficient and extend the initial visit substantially.
In women over 45, diagnosis rests on history and symptom pattern rather than a hormone level, because FSH fluctuates too widely. Testing is more useful for excluding other explanations, and under 45 it carries more weight.
Very little. The requirements are principally clinician education, written protocols, documentation, patient education materials and referral pathways.
Patients with a history of hormone-sensitive cancer, unexplained abnormal bleeding, complex cardiovascular or thrombotic history, suspected primary ovarian insufficiency, and any presentation that does not fit the expected picture.
A review at around three months after starting treatment is a common and defensible cadence, with ongoing review thereafter. Treatment in this area is iterative rather than one-off.
Scope of practice varies by state and by credential. Where prescribing authority allows, NPs and PAs run menopause services successfully, and EncorVita education is designed for the interprofessional team.
